Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CDK4 inhibitor

DRUG CLASS:

CDK4 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

PF-07220060 (1)

PF-07220060 (1)

›

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor Sensitive : A2	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive : A2	Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : B	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : B
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	PF-07220060 Sensitive: C2 – Inclusion Criteria PF-07220060 Sensitive : C2	PF-07220060 Sensitive: C2 – Inclusion Criteria PF-07220060 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive : C2	CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive : C2
HMGB1 positive	Breast Cancer	HMGB1 positive	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
IGF1R amplification	HER2 Positive Breast Cancer	IGF1R amplification	HER2 Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
35-gene signature	Estrogen Receptor Positive Breast Cancer	35-gene signature	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ER negative + HER-2 negative	HER2 Negative Breast Cancer	ER negative + HER-2 negative	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3